We are excited to present subject matter expertise on topics that impact the global clinical research community..."
SEATTLE, WA (PRWEB) April 25, 2017
Leaders of Quorum Review IRB and Kinetiq, the consulting and technology division of Quorum, will be featured in multiple sessions at this week’s Association of Clinical Research Professionals (ACRP) 2017 Meeting & Expo with topics that range from emerging trends to best practices in clinical research.
"We are excited to present subject matter expertise on topics that impact the global clinical research community at this year’s ACRP Meeting—just a few blocks from our headquarters here in Seattle," says Quorum CEO Cami Gearhart. "Seattle has always been a hub of innovation and collaboration and we look forward to representing the best in northwest biomedical research."
Quorum CEO Cami Gearhart will host an eConsent panel featuring Kinetiq Senior Regulatory Analyst Jessica Huening, as well as site and industry experts Linda Coleman, Director of Human Research Protection Program, and Phil Coran, Senior Director of Quality and Regulatory Affairs. The panelists will discuss the issues sites should consider when considering the use of an eConsent tool. The panel discussion will take place on Saturday, April 29 at 2:30 p.m.
James Riddle, Vice President of Client Services for Kinetiq, will be featured in two breakout sessions. First, he will present on layperson summaries and whether or not the U.S. should follow the E.U. example, outlining new E.U. requirements and how the U.S. might adopt or structure its own version of layperson summaries. This session is scheduled for Sunday, April 30 at 9:50 a.m. Later in the day, James will present on the regulatory and ethical implications of melding consumer big data with medical data in a research setting. This session will occur on Sunday, April 30 at 3:45 p.m.
On Tuesday, May 2 at 9:45 a.m., Mitchell Parrish, Kinetiq VP of Legal and Regulatory Affairs, will lead a session on obtaining consent in acute settings. Attendees will learn three ways to overcome the inherent difficulties of obtaining participant research consent in acute healthcare settings. Join Mitchell to learn the pros, cons, and regulatory support for each in this exciting session.
Kinetiq Manager of Legal Affairs, Dominic Chiarelli, and Regulatory Attorney, David Babaian, will host a 1-hour breakout session about recent legal and regulatory changes. This session will identify recently proposed and adopted legislative and regulatory initiatives affecting clinical research. Join Dominic and David Tuesday, May 2 at 9:45 a.m.
Finally, Michelle Grienauer, Senior Regulatory Attorney for Kinetiq, will present on a trending topic in ethical research: returning research results. This presentation will lay out best practices to help navigate the ethical and legal issues surrounding the return of research test results. Join Michelle on Tuesday, May 2 at 11:00 a.m.
Visit Quorum and Kinetiq in the exhibit hall to participate in a short survey and receive a Starbucks gift card. Gift cards are first come, first serve.
Quorum Review IRB is the first name in streamlined, service-centered independent ethics and regulatory review. The Quorum difference is One-Touch Collaboration™. Your research benefits from an outstanding service experience, a single point of contact, one study startup timeline, and a true single board review—which is why Quorum is the preferred central IRB. Beyond traditional institutional review board services, Quorum offerings include single IRB (sIRB) services for institutions and the world’s first IRB-integrated electronic informed consent solution: Q Consent™. Kinetiq, the consulting and technology division of Quorum, provides services that enhance and optimize the clinical research process.
Kinetiq is a consulting and technology division of Quorum that delivers innovative solutions to the challenges of human subject protections and compliance in clinical research. Kinetiq works with clinical researchers, research institutions, pharmaceutical, biotechnology, and medical device companies—as well as others around the world—to develop contemporary approaches to a changing landscape.